Table 4 The incremental comparison of ICERs for different medication scenarios
From: Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes
Relative effectiveness | 1. EMRÂ +Â symptoms vs 0. No screening | 5. Echocardiography vs 1. EMRÂ +Â symptoms |
|---|---|---|
Men (%) | ||
 0 | €6115 | €29,100 |
 10 | €5573 | €27,552 |
 20 | €5067 | €26,157 |
 30 | €4591 | €24,895 |
 40 | €4140 | €23,749 |
 50 | €3709 | €22,705 |
 60 | €3293 | €21,753 |
 70 | €2890 | €20,880 |
 80 | €2494 | €20,079 |
 90 | €2102 | €19,341 |
 100 | €1711 | €18,660 |
Women (%) | ||
 0 | €6318 | €39,326 |
 10 | €5888 | €38,122 |
 20 | €5496 | €37,015 |
 30 | €5137 | €35,998 |
 40 | €4807 | €35,067 |
 50 | €4502 | €34,216 |
 60 | €4219 | €33,442 |
 70 | €3995 | €32,741 |
 80 | €3706 | €32,110 |
 90 | €3471 | €31,547 |
 100 | €3248 | €31,049 |